Answers are grounded in this paper and cite their sources.
to the editor: In their report on 10 years of alendronate therapy for osteoporosis in postmenopausal women, Bone et al. (March 18 issue) 1 mention the long retention time of alendronate in bone as an advantage. This view is based on the fact that the large reduction in bone turnover is present five years after the discontinuation of treatment. The authors claim that histomorphometric analysis confirmed long-term bone safety, 2,3 but the study they cite followed treatment for only two to three years in a small group of patients receiving 20 mg of alendronate. 2 What the present study actually shows is that two years of therapy with 20 mg of alendronate followed by three years’ treatment with 5 mg suppresses bone turnover to a degree from which it may not recover. This result is consistent with data from a study in Danish women, which showed that two years of treatment with 20 mg of alendronate led to a reduction in bone turnover that did not return to baseline five years after the discontinuation of therapy. 4 In contrast, with two years of therapy with 2.5 mg or 5 mg of alendronate, 5 bone turnover returned to placebo levels two years after discontinuation. Thus, the long-term safety with 20 mg of alendronate has not been established.
No takes yet. Share an insight, caveat, or question.
Sl et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: